Clinical trials: Ribavirin
Chronic Hepatitis C
Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected Patients
This study will evaluate the efficacy and safety of MP-424 with Peginterferon Alfa-2b and Ribavirin (RBV) in patients with genotype 2 hepatitis C, who relapsed after previous treatment.
- Trial name
- NCT01466192
- Testing
- MP-424 (generic name:Telaprevir), Ribavirin, Peginterferon alfa-2b
- Where
- Japan
- Volunteers
- 108 people
- Sponsor
- Tanabe Pharma Corporation
Chronic Hepatitis C
Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Non-responder Genotype 2 Hepatitis C Infected Patients
This study will evaluate the efficacy and safety of MP-424 with Peginterferon Alfa-2b and Ribavirin (RBV) in patients with genotype 2 hepatitis C, who did not respond to previous treatment.
- Trial name
- NCT01468584
- Testing
- MP-424 (generic name:Telaprevir), Ribavirin, Peginterferon alfa-2b
- Where
- Japan
- Volunteers
- 10 people
- Sponsor
- Tanabe Pharma Corporation
Chronic Hepatitis C(CHC)
Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC)
This study will evaluate the efficacy and safety of MP-424 with IFN beta and RBV in patients with genotype 1/2 hepatitis C, who are treatment-naïve or have received its treatment before.
- Trial name
- NCT01753570
- Testing
- MP-424, RBV(24 weeks), IFN beta(24 weeks)
- Where
- Japan
- Volunteers
- 74 people
- Sponsor
- Tanabe Pharma Corporation
COVID19
Study to Evaluate the Safety and Efficacy of VIRAZOLE® in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19_#2
This study is a Phase 1, open label, non-randomized, two-arm interventional clinical trial to evaluate the safety and efficacy of Virazole® in hospitalized adult patients who have tested positive for COVID-19 and, as a result…
- Trial name
- NCT04356677
- Testing
- 50 mg/mL Virazole, 100 mg/mL Virazole
- Sponsor
- Bausch Health Americas, Inc.
Hepatitis C, HIV Infections
HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon /Ribavirin
The primary objective of this study is to evaluate the safety and efficacy of a Response Guided Therapy of boceprevir 800 mg dosed three times a day (TID) orally (PO) in combination with Peginterferon (either alpha 2b or alpha…
- Conditions
- Hepatitis C, HIV Infections, COINFECTION
- Trial name
- BOC-HIV (NCT01718301)
- Testing
- boceprevir, Ribavirin, Peginterferon alfa-2a
- Where
- Spain
- Volunteers
- 108 people
- Sponsor
- Anna Cruceta
Chronic Hepatitis C
Study of the Pharmacokinetic Action of Amantadine and Ribavirin in Chronic Hepatitis C. CINAM
Peg interferon and ribavirin currently represent the standard approved association for treating patients infected with hepatitis C virus (HCV) .
- Trial name
- CINAM (NCT00199719)
- Testing
- Ribavirine
- Where
- 2 sites in France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Limoges
Malignant Solid Tumor
Phase I/II Study of Ribavirin Given as Monotherapy in Solid Tumour Cancer Patients
The purpose of this study is to learn whether oral Ribavirin is safe and effective in treating patients with solid tumour cancers, that have high levels of the protein eIF4E.
- Trial name
- NCT01309490
- Testing
- Ribavirin
- Where
- Canada
- Volunteers
- 5 people
- Sponsor
- Jewish General Hospital
BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
Pembrolizumab (MK-3475) in Hepatocellular Carcinoma
This will be a Phase II study investigating single agent pembrolizumab (Keytruda®) as a second-line therapy for subjects with hepatocellular carcinoma (HCC) who either progressed on or after sorafenib or did not tolerate…
- Conditions
- BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Hepatitis C Infection, Refractory Liver Carcinoma
- Trial name
- NCT02940496
- Testing
- Elbasvir/Grazoprevir, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Respiratory Syncytial Virus, Respiratory Syncytial Virus, Human
Assessing Antiviral Treatments in Early Symptomatic RSV
This trial will use a previously validated platform, to quantitatively assess antiviral effects in low-risk patients with high viral burdens and uncomplicated Respiratory Syncytial Virus (RSV), to determine in-vivo antiviral…
- Trial name
- ARSYNAL-FC (NCT06488300)
- Testing
- Ribavirin, Molnupiravir, Favipiravir
- Where
- 2 sites in Laos, Thailand
- Volunteers
- 1,000 people
- Sponsor
- University of Oxford
Chronic Hepatitis C
Study of the Efficacy and Safety of Pegnano Plus Barivir (Ribavirin) in Treatment-naïve Patients With Chronic Hepatitis C at KienGiang General Hospital
This study presents a clinical study on the efficacy and safety of Pegnano combined with Barivir (Ribavirin) in treating treatment-naïve patients with Chronic Hepatitis C at Kien Giang General Hospital.
- Trial name
- NCT06922643
- Testing
- Peginterferon Alfa-2A, Ribavirin Oral Product
- Volunteers
- 100 people
- Sponsor
- Nanogen Pharmaceutical Biotechnology Joint Stock Company
Hemorrhagic Fever With Renal Syndrome
Ribavirin for Hemorrhagic Fever With Renal Syndrome
Hemorrhagic Fever with Renal Syndrome (HFRS) is caused by a virus acquired by contact with chronically infected rodent hosts. HFRS is present throughout Korea.
- Trial name
- NCT00623168
- Testing
- Ribavirin
- Where
- South Korea
- Sponsor
- U.S. Army Medical Research and Development Command
Dengue Fever, Dengue Hemorrhagic Fever
The Comparative Efficacy of Standard Treatment Plus Ribavirin vs Standard Treatment Alone in Preventing Clinically Significant Hemorrhage in Patients With Dengue Fever
This study investigates the comparative efficacy of standard treatment plus Ribavirin versus standard treatment alone in preventing clinically significant hemorrhage among patients diagnosed with dengue fever.
- Conditions
- Dengue Fever, Dengue Hemorrhagic Fever, Severe Dengue
- Trial name
- NCT06744777
- Testing
- Ribavirin, Standard Treatment
- Where
- 4 sites in Pakistan
- Volunteers
- 284 people
- Sponsor
- Khyber Medical University Peshawar
Liver Transplantation, Hepatitis C
Pilot Study Evaluate Efficacy of Grazoprevir + Elbasvir for 12 or 16 Weeks in Liver Transplant Recipients.
Pilot, single center, open-label study to evaluate the efficacy and tolerability of Grazoprevir and Elbasvir in HCV GT1 and 4 liver transplant recipients.30 liver transplant recipients with hepatitis C recurrence.
- Trial name
- EGRADICATE (NCT02890719)
- Testing
- Grazoprevir 100 mg/day, Elbasvir 50 mg/d, Elbasvir 50 mg/day
- Sponsor
- Fundacion Clinic per a la Recerca Biomédica
Chronic Hepatitis C Infection, Genotype 1
A Phase 1b/2a Study of SC Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis C
This is an open-label, randomized, safety, tolerability, dose-finding, PK/PD, and preliminary efficacy study of subcutaneous Hanferon™ in combination with ribavirin(RBV) in treatment-naïve subjects with genotype 1 hepatitis C.
- Trial name
- NCT01194037
- Testing
- recombinant variant of interferon-alpha 2b, Peginterferon alfa-2a, Ribavirin
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- HanAll BioPharma Co., Ltd.
Chronic Hepatitis C Infection
Switching Regimen in Treating Cirrhotic HCV GT1b Subjects
This is a prospective, randomized study to evaluate the efficacy and safety of switching treatment from Peg-interferon and Ribavirin to direct-acting antiviral agents in Chinese with CHC genotype 1b infection, who are…
- Trial name
- SWITCH-1 (NCT02583685)
- Testing
- PR4 + LDV/SOF + ASV 4 wk, PR4 + LDV/SOF + SMV 4 wk, PR4 + LDV/SOF + ASV 6 wk
- Where
- 2 sites in China
- Volunteers
- 138 people
- Sponsor
- Humanity and Health Research Centre
Lassa Fever
LAssa Fever Adjunct Treatment With DEXamethasone
Dexamethasone is a corticosteroid which can modulate inflammatory-mediated tissue damage associated with a wide range of infectious diseases.
- Trial name
- LADEX (NCT06222723)
- Testing
- Dexamethasone, Ribavirin
- Where
- Nigeria
- Volunteers
- 42 people
- Sponsor
- Bernhard Nocht Institute for Tropical Medicine
Hepatic Insufficiency
Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic Impairment
The primary objectives were: To determine the effects of steady state TPV co-administered with low dose RTV on steady state PegIFN and RBV in HIV negative subjects with mild hepatic impairment (scheme A) To determine the effects…
- Trial name
- NCT02259855
- Testing
- Tipranavir, Ritonavir, Pegylated interferon
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Liver Cancer
Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy
To learn if giving immune checkpoint therapy (such as atezolizumab) and bevacizumab to patients who have HCC and are receiving DAAs may help to control HCC and hepatitis C.
- Trial name
- NCT05717400
- Testing
- Bevacizumab, Atezolizumab, Sofosbuvir
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- M.D. Anderson Cancer Center
Hepatitis C Virus
Understanding HCV Reinfection Rates in an Incarcerated Population After Cure With Interferon Free HCV Treatment
This pilot study is crucial to determining whether treating individuals who are at high risk for transmission or re-infection will impact HCV reinfection rates.
- Trial name
- NCT02460133
- Testing
- Paritaprevir, Ritonavir, Dasabuvir
- Volunteers
- 44 people
- Sponsor
- Nova Scotia Health Authority
Healthy
Ribavirin 200 mg Tablets Under Fasting Conditions
The objective of this study is to compare the relative bioavailability of ribavirin 200 mg tablets (manufactured by TEVA Pharmaceutical Industries, Ltd.
- Trial name
- NCT00835146
- Testing
- Ribavirin 200 mg tablets, COPEGUS™
- Where
- 2 sites in United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA